The company announced its results forecast for the first three quarters. Net profit attributable to shareholders of listed companies for the first three quarters was 63-680 million, an increase of 150% over the previous year. We expect a sharp increase in the company's performance over the same period last year. On the one hand, there was a significant increase in the performance of many subsidiaries, especially the holding subsidiary's large and sharp increase in performance. On the other hand, the company's sale of Baoan Real Estate received 8.2 investment income. This move will significantly increase current profit and loss. The company's performance was in line with expectations. On the other hand, the company invested 1 billion yuan to set up a graphite industrial park base in Harbin, which is scheduled to be completed in 2019. The base specializes in the development and production of new materials related to graphite and carbon. This move is an important step for the company to expand Betray's upstream business. By setting up an industrial park base, on the one hand, it can better control upstream graphite resources, and on the other hand, it can also better connect them with downstream graphite anode material production, which plays a critical role in integrating the company's industrial chain. The company is currently committed to three main businesses: new energy, new materials, financial investment, and pharmaceuticals. Currently, Betray, one of the company's three platforms, has huge room for growth. It also has many important technical reserves, including silicon-carbon anode materials, lithium cathode materials, and graphene, and has strong technical strength. The net profit for 2015-2016 is expected to be 162 million and 186 million. In the future, the company will focus on breaking through the field of new energy power batteries and also getting involved in the cathode material NCA. In addition, the company has a large amount of natural graphite ore resources, and the annual production of graphite concentrate can reach 600,000 tons. Ma Yinglong's growth is relatively certain. It is expected to grow by about 10% to 20% every year. The company is actively expanding the anorectal hospital business and setting up an industrial fund to seek more industrial opportunities. The net profit for 2015-2016 is estimated to be 240 million and 300 million, respectively, and the corresponding company's investment income is around 72 million and 90 million. Meanwhile, among PE investment companies, Dadi and the industry benefiting from a sharp increase in downstream demand for new energy electric vehicles, their performance has skyrocketed, and this year's performance is expected to triple over the same period last year. Furthermore, the controlled Vidajian genetic testing company will benefit from the liberalization of genetic testing policies in the future and become an important engine for the company's performance growth. The company's EPS for 2015-2017 is expected to be 0.55 yuan, 0.26 yuan, and 0.31 yuan respectively, corresponding to 21 times the PE this year, maintaining a highly recommended -A rating. Risk warning: Investments in the financial sector are subject to certain volatility, which may affect current results.